Laurie Keating

Laurie Keating is the Chair of PepGen’s Board of Directors. In addition to her role at PepGen, Laurie also serves as a Director of Immuneering Corp (Nasdaq: IMRX) and Imago Biosciences (Nasdaq: IMGO) and has served for more than ten years on the Board of MassBio. Laurie previously served as the Executive Vice President, General Counsel, and Corporate Secretary of Alnylam Pharmaceuticals. In this role, she led global government affairs, legal, IP, litigation, and compliance, and advised the Board on financing and strategic collaborations, governance, and corporate strategy. Prior to Alnylam, she served as SVP, General Counsel, and Corporate Secretary of Millennium Pharmaceuticals, a commercial-stage company that was later acquired by Takeda. At Millennium, Laurie led the global Legal, Intellectual Property, Corporate Quality, and Compliance groups. Prior to Millennium, Laurie was the founding CEO and a director of Hydra Biosciences. Her contributions and executive leadership at public high technology companies earlier in her career led to her being named one of the 45 most influential in-house lawyers in the U.S. under the age of 45. Laurie earned her bachelor’s degree in Economics from the University of California at Berkeley, and her JD from the University of California, Hastings College of the Law.